NYLIM
CORT icon

New York Life Investment Management’s Corcept Therapeutics CORT Stock Holding History

New York Life Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,407
Closed -$363K – 968
2024
Q1 		$363K Buy
+14,407
New +$340K ﹤0.01% 1148
2023
Q1 		– Sell
-25,188
Closed -$512K – 1241
2022
Q4 		$512K Buy
25,188
+2,701
+12% +$67.7K 0.01% 913
2022
Q3 		$577K Buy
22,487
+1,779
+9% +$47.6K 0.01% 681
2022
Q2 		$492K Buy
+20,708
New +$451K 0.01% 731

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

New York Life Investment Management's CORT Position: Q2 2024 in Review

New York Life Investment Management sold out of Corcept Therapeutics (CORT) in Q2 2024, closing a stake of 14,407 shares — an estimated $363K sold.

New York Life Investment Management first reported a position in CORT in Q2 2022 and held it in 4 quarters. The position peaked at $577K in Q3 2022. 285 funds tracked by Wall St. Rank hold CORT as of Q2 2024.

  • New York Life Investment Management reported no remaining Corcept Therapeutics position as of Q2 2024 after selling out during the quarter.
  • New York Life Investment Management sold 14,407 Corcept Therapeutics shares in Q2 2024, an estimated $363K.
  • New York Life Investment Management first reported a position in Corcept Therapeutics in Q2 2022 and held it in 4 quarters.
  • New York Life Investment Management's Corcept Therapeutics position peaked at $577K in Q3 2022.
  • 285 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2024.

Based on New York Life Investment Management's 13F filing for Q2 2024, filed 5 Aug 2024.